SynthesisBMC public health2025
Temporal changes in prevalence and geographical distribution of human papillomavirus infection in mainland China: a systematic review and analysis of 1.07 million females from 2010 to 2021.
Synthesis in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world effectiveness of HPV vaccination against high-risk type HPV DNA positivity among adult women aged 18 - 45years in China: A matched test-negative design study.Human vaccines & immunotherapeutics · 2026Article
- Burden and Risk Factor Patterns of Reproductive System Tumors and Non-Tumor Diseases Among Asian Women, 1990-2021: Evidence from the GBD Study.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman papillomavirus (HPV) has been identified as a causative agent of cervical cancer. The aim of this study was to investigate temporal changes in prevalence and geographical distribution of human papillomavirus (HPV) infection in mainland China.
methodsThis study was a systematic review and aggregate data analysis. The literature was searched from multiple databases. The included studies were divided into two groups, the 2010-2016 group and the 2017-2021 group, according to the time period of specimen collection. A total of 17 HPV types were selected. Temporal changes in prevalence and geographical distribution of HPV infection and the effect of the HPV vaccine were analyzed.
resultsA total of 1,073,296 females from mainland China were included. The total prevalence of the 17 selected HPV types in 2017-2021 was 26.06% which was significantly higher than the 23.20% in 2010-2016 (P < 0.001). The total prevalence of the 17 selected HPV types significantly increased in 11 regions, among which Jiangxi, Beijing, Chongqing, Inner Mongolia, and Zhejiang increased by more than 1.5 times in 2017-2021 compared to 2010-2016 (P < 0.05). The national prevalence of HPV51, 59, 53, 56, 39, 45, 66, 52, 35, 68 and 58 significantly increased (P < 0.001), while the prevalence of HPV33, 16, 6, and 11 significantly decreased (P < 0.05) in 2017-2021 compared to 2010-2016. The national prevalence of HPV 52, 16, 58, 53, and 51 ranked in the top 5 from 2017-2021. A 10.05% reduction in the national prevalence of 2-HPV type targeted by bivalent vaccine and a 13.09% reduction in that of 4-HPV type targeted by quadrivalent vaccine were found from 2010-2016 through 2017-2021.
conclusionsThe prevalence of HPV infection among females remains high and shows a significant increase in the mainland China. The top five most common HPV types in females in 2017-2021 were HPV 52, 16, 58, 53 and 51. Although some effectiveness of HPV vaccination has already been observed, particular attention should be paid to the high prevalence of nonvaccine genotypes including HPV 53 and HPV 51 in mainland China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.